Li-juan Shi et al. confirmed that oxymatrine could alleviate hepatic steatosis and serum lipids level via down-regulating Srebf1 and up-regulating Pparα mediated metabolic pathways [34]. The gene discussed is SREBF1; the disease is Hepatic steatosis.